TG Therapeutics Announces Data from the ULTIMATE I and II Phase 3 Trials of BRIUMVI in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK - TG Therapeutics, Inc. , today announced the details of an upcoming oral presentation, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI in patients with... | June 1, 2023

Related Keywords

Colorado ,United States ,Lawrence Steinman ,Enrique Alvarez ,Consortium Of Multiple Sclerosis Centers ,International Journal ,Biopharmaceutical Company ,Stanford University ,Neurological Sciences ,Tg Therapeutics Inc ,University Of Colorado ,Nasdaq ,Exchange Commission ,Multiple Sclerosis Centers ,Ublituximab Is Associated ,Significant Improvement ,Disease Modifying Therapies ,Expanded Disability Status Scale ,Private Securities Litigation Reform Act ,Annual Report ,News Publishing ,Tg Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Few ,Work ,G ,Oday ,Nnounced ,The ,Details ,F ,N ,Pcoming ,Mural ,Ighlighting ,Data ,Rom ,Ultimate , ,Hi ,Hase ,Trials ,Valuating ,Riumvi ,Atients Tgtx Us88322q1085 ,